Plasmodium vivax is a significant cause of morbidity and death, and the most prevalent human malaria species in Asia and South America. Primaquine is the primary treatment for P.vivax. Currently, the WHO recommends a 14-day primaquine regimen of 0.5mg/day for the P.vivax strain in Asia. However, a major limitation to primaquine treatment is an unknown glucose-6-phosphate-dehydrogenase deficiency, or G6PD, status of a patient, exposing them to a risk of hemolysis and consequently, risk of death. In this study, we aimed to assess the barriers to point-of-care G6PD testing in P.vivax malaria patients in Peninsula and Borneo, Malaysia. 

Mentors: Ingrid Chen PhD, Roland Gosling MD PhD, Benedikt Ley PhD